BRF110 prevents dopaminergic neuron demise and striatal dopaminergic denervation in vivo. Remarkably, besides neuroprotection, BRF110 up-regulates TH, DDC and GCH1 transcription and increases striatal DA in the PD mouse model [85]. Here, GCH1 is linked to Parkinson disease.